Regulatory approval

Published by the Health Canada.

Health Canada approved entrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.

This is written in the approval document as:

ROZLYTREK (entrectinib) is indicated for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.

Citation

Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Entrectinib